|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This review highlights the enhanced activity of PIM kinases in cancer that can be driven by hypoxia in the tumour microenvironment and the important role that aberrant PIM kinase activity plays in resistance mechanisms to chemotherapy, radiotherapy, anti-angiogenic therapies and targeted therapies.
|
31836451 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Murine melanoma B16 was established subcutaneously and treated by transferring tumor epitope gp100-reactive T cells along with treatment regimen that involved inhibiting PIM kinases, anti-PD1 or both.
|
30327305 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Depletion of PIM1 decreased cell proliferation, migration, invasion and colony formation in vitro, as well as reduced tumor growth in vivo.
|
30583073 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The constitutively active serine/threonine kinase proviral integration site for moloney murine leukemia virus 1 (PIM1) was recently found to be overexpressed in GB patient samples and to maintain cell survival in these tumors.
|
30389373 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accordingly, pharmacological inhibition of c-Abl together with Aurora resulted in substantial cell death and tumor regression <i>in vivo</i> The findings reveal an important functional interaction between NIK, Abl and Aurora kinases, and identify the NIK, c-Abl and PIM survival kinases as potential pharmacological targets for improving the efficacy of Aurora inhibitors in myeloma.
|
30948493 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway.
|
31114247 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mir-33a was demonstrated to act as a tumor suppressor in larnygeal cancer via directly targeting the 3' untranslated region of PIM1.
|
30102806 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with PIM kinase inhibitors reverses this resistance phenotype, making tumors increasingly susceptible to small-molecule therapeutics, which block the PI3K-AKT pathway.
|
30190422 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo experiments further confirmed that knockdown of Pim1 inhibits the growth of tumors derived from the SKOV3 cell line.
|
30349298 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PIM1, a serine/threonine kinase, plays an essential role in tumorigenesis of multiple types of tumors.
|
30464610 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The rationale for this therapeutic approach is based on the fact that antiangiogenic drugs can make tumors hypoxic, and thus more sensitive to PIM inhibitors.<b>Experimental Design:</b> Xenograft and orthotopic models of prostate and colon cancer were used to assess the effect of PIM activation on the efficacy of VEGF-targeting agents.
|
29084916 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pim1-silenced cells were more vulnerable to glucose starvation, and Pim1-induced tumor proliferation or tolerance to glucose starvation was attenuated by blocking the Warburg effect.
|
29516572 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PIM-1 expression levels were significantly associated with tumor size, lymph node involvement, nerve invasion, distant metastasis and weakly associated with tumor node metastasis stage.
|
29399171 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, more and more studies including ours have found that PIM1 can induce senescence in normal human diploid fibroblasts and behave as a tumor suppressor.
|
29763603 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
|
28698206 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These compounds induce tumour cell death and enhance cytotoxicity with chemotherapeutic agents and targeted compounds, including PIM kinase inhibitors.
|
29045385 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The possible end-point is an increased percentage of cancer stem cells, which may be partly responsible for the therapy resistance found in tumors overexpressing PIM kinases.
|
28938604 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In summary, we revealed that miR-638 functions as a tumor suppressor through inhibiting PIM1 expression in OS.
|
28050866 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings warrant clinical evaluation of PIM kinase inhibitors in patients with TN tumors that have elevated MYC expression.
|
27775705 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There is also a correlation with markers of cancer stem cells, which may contribute to the therapy resistance found in tumors overexpressing PIM kinases.
|
27901106 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using knockdown studies, we showed that PIM1 contributes to melanoma cell proliferation and tumor growth in vivo; however, the presence of PIM2 and PIM3 could also influence the outcome.
|
27448973 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, both PIM kinases have a reported synergistic effect with c-MYC in mediating tumour development in several cancers, c-MYC gene being translocated to one of the immunoglobulin loci in nearly all BLs.
|
26643319 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Twelve tumors with matching normal renal tissue implicated increased PIM's and MAPKAPK's in tumors compared to adjacent normal renal tissue.
|
26406598 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Taken together, PIM1 is up-regulated by hypoxia in HCC and promotes tumor growth and metastasis through facilitating cancer cell glycolysis.
|
25834102 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
|
24799066 |
2014 |